Axon Enterprise, Inc $AXON Shares Sold by Vivid Wealth Management LLC

Key Points

• Vivid Wealth Management LLC reduced its holdings in Axon Enterprise by 18.6%, now owning 3,375 shares worth approximately $2.79 million as of the latest SEC filing.
• Analysts have rated Axon Enterprise with a consensus rating of "Moderate Buy", and fourteen analysts have issued Buy ratings along with price targets ranging from $800.00 to $855.00.
• Axon reported $2.12 EPS for the last quarter, exceeding estimates by $0.58, with revenues of $668.54 million, marking a 32.6% year-over-year increase.

Vivid Wealth Management LLC trimmed its holdings in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 18.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,375 shares of the biotechnology company's stock after selling 770 shares during the quarter. Vivid Wealth Management LLC's holdings in Axon Enterprise were worth $2,794,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of AXON. Brighton Jones LLC acquired a new stake in Axon Enterprise in the 4th quarter valued at about $480,000. Yousif Capital Management LLC lifted its holdings in Axon Enterprise by 1.6% in the 1st quarter. Yousif Capital Management LLC now owns 9,961 shares of the biotechnology company's stock valued at $5,239,000 after acquiring an additional 157 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new stake in Axon Enterprise in the 1st quarter valued at about $587,000. GAMMA Investing LLC lifted its holdings in Axon Enterprise by 11.8% in the 1st quarter. GAMMA Investing LLC now owns 1,454 shares of the biotechnology company's stock valued at $765,000 after acquiring an additional 154 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its holdings in Axon Enterprise by 12.3% in the 1st quarter. Handelsbanken Fonder AB now owns 41,902 shares of the biotechnology company's stock valued at $22,038,000 after acquiring an additional 4,600 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AXON. Weiss Ratings reissued a "hold (c)" rating on shares of Axon Enterprise in a report on Wednesday. UBS Group restated a "neutral" rating and set a $840.00 price objective (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Raymond James Financial restated an "outperform" rating and set a $855.00 price objective (up previously from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Zacks Research downgraded Axon Enterprise from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 2nd. Finally, Northland Securities set a $800.00 price objective on Axon Enterprise in a report on Tuesday, August 5th. Fourteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, Axon Enterprise currently has a consensus rating of "Moderate Buy" and an average target price of $841.64.

Insider Buying and Selling

In other Axon Enterprise news, Director Hadi Partovi bought 1,358 shares of the company's stock in a transaction dated Wednesday, August 13th. The shares were bought at an average price of $740.00 per share, for a total transaction of $1,004,920.00. Following the acquisition, the director directly owned 237,938 shares of the company's stock, valued at approximately $176,074,120. This trade represents a 0.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Brittany Bagley sold 5,000 shares of the company's stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $713.88, for a total value of $3,569,400.00. Following the completion of the transaction, the chief financial officer owned 93,592 shares in the company, valued at $66,813,456.96. This represents a 5.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,932 shares of company stock worth $45,115,616 over the last ninety days. 4.40% of the stock is currently owned by corporate insiders.

Axon Enterprise Price Performance

NASDAQ AXON opened at $734.04 on Friday. The company has a market cap of $57.63 billion, a PE ratio of 181.24, a PEG ratio of 28.25 and a beta of 1.41. Axon Enterprise, Inc has a 1 year low of $422.38 and a 1 year high of $885.91. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The stock's 50-day moving average price is $756.36 and its two-hundred day moving average price is $711.76.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.58. The company had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm's quarterly revenue was up 32.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.